1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PSMAddition: A phase III trial to compare treatment with (177)Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer
    Meeting Abstract

    Tagawa, S. T.; Sartor, O.; Saad, F.; Sakharova, O.; de Bono, J.; Feng, F.; Fizazi, K.; Morris, M. J.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • PSMAfore: A phase III study to compare (177)Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naive patients with mCRPC
    Meeting Abstract

    Morris, M. J.; Sartor, O.; Chi, K. N.; de Bono, J. S.; Shore, N. D.; Crosby, M.; Dalal, D.; Fizazi, K.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update
    Meeting Abstract

    Choueiri, T. K.; Eto, M.; Kopyltsov, E.; Rha, S. Y.; Porta, C. G.; Motzer, R.; Grünwald, V.; Hutson, T. E.; Méndez-Vidal, M. J.; Hong, S. H.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Motzer, R. J.; Tannir, N. M.; McDermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Plimack, E. R.; Porta, C. G.; George, S.; Powles, T. B.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Safety of tazemetostat (TAZ) in combination with abiraterone/prednisone (A/P) or enzalutamide (E) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Abida, W.; Iannotti, N.; Kocabas Argon, E.; Appleman, L.; Michaud, N.; Rajarethinam, A.; Adib, D.; Saltzstein, D. R.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Biochemical response (PSA0) and testosterone (T) recovery in Metacure, a multi-arm multi-modality (MM) therapy (tx) for very high risk localized (HRL) and low volume metastatic (LVM) prostatic adenocarcinoma
    Meeting Abstract

    Teo, M. Y.; McBride, S.; Gopalan, A.; Benoliel, H.; Eastham, J. A.; Goh, A.; Szmulewitz, R.; Morgans, A. K.; Bubley, G.; Gupta, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Zhao, J. L.; Antonarakis, S.; Cheng, H.; George, D. J.; Aggarwal, R. R.; Abida, W.; Decker, B.; Smart-Curley, T.; Schonhoft, J.; Anderson, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Chromosomal instability (CIN) biomarker in circulating tumor cells (CTC) may predict for therapy resistance in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Keegan, N. M.; Schonhoft, J.; Barnett, E.; Cohn, E. D.; Zhao, J. L.; Carbone, E. A.; Zanone, M. R.; Anderson, A.; Wenstrup, R.; Scher, H. I.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Oudard, S. M.; Bevans, K. B.; Attard, G.; Efstathiou, E.; Flaig, T. W.; Franke, F. A.; Goodman, O. B. Jr; De Giorgi, U.; Pieczonka, C. M.; Yeruva, K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Fizazi, K.; Herrmann, K.; Krause, B. J.; Rahbar, K.; Chi, K. N.; Morris, M. J.; Sartor, O.; Tagawa, S. T.; Kendi, A. T.; Vogelzang, N. J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save